{"denoms":[{"counts":[{"groupId":"BG000","value":"19"}],"units":"Participants"}],"groups":[{"description":"This was a single arm study for myeloma patients with \\<12 months of prior treatment to determine whether the incorporation of bortezomib into a tandem transplant regimen followed by 2 years of maintenance therapy would increase event-free survival.","id":"BG000","title":"Tandem Transplant in MM <12 Mos of Prior Treatment"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"16"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Enrollment halted prematurely. Study met stopping rules. Outcomes will not be tracked and published","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"49","upperLimit":"70.6","value":"59.4"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEAN","populationDescription":"Enrollment halted prematurely. Study met stopping rules. Outcomes will not be tracked and published","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"11"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Enrollment halted prematurely. Study met stopping rules. Outcomes will not be tracked and published.","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"19"}]}],"title":"United States"}],"paramType":"NUMBER","populationDescription":"Enrollment halted prematurely. Study met stopping rules. Outcomes will not be tracked and published","title":"Region of Enrollment","unitOfMeasure":"participants"}]}